CA Patent

CA3068414A1 — Combination therapy to treat urea cycle disorders

Assigned to Baylor College of Medicine · Expires 2019-01-03 · 7y expired

What this patent protects

Embodiments of the disclosure include certain formulations for methods of treating urea cycle disorders. The methods encompass compositions that comprise benzoate and phenylbutyrate that may be at certain doses and have certain ratios of the components. The benzoate and phenylbut…

USPTO Abstract

Embodiments of the disclosure include certain formulations for methods of treating urea cycle disorders. The methods encompass compositions that comprise benzoate and phenylbutyrate that may be at certain doses and have certain ratios of the components. The benzoate and phenylbutyrate may act synergistically in treatment of the urea cycle disorders, in particular embodiments.

Drugs covered by this patent

Patent Metadata

Patent number
CA3068414A1
Jurisdiction
CA
Classification
—
Expires
2019-01-03
Drug substance claim
No
Drug product claim
No
Assignee
Baylor College of Medicine
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.